Setmelanotide

Setmelanotide is a cyclic octapeptide agonist of the melanocortin-4 receptor (MC4R), a key node of the hypothalamic leptin-melanocortin pathway that regulates hunger and energy balance. In rare monogenic obesities, upstream signalling is disrupted — for example by loss-of-function variants in POMC, PCSK1 or LEPR — so the MC4R is under-stimulated and patients experience severe early-onset obesity and hyperphagia. By directly agonising MC4R downstream of the genetic defect, setmelanotide restores anorexigenic signalling, reducing hunger and body weight. Its effect depends on an intact MC4R, which is why it targets specific genetic and syndromic diagnoses rather than common obesity.

Setmelanotide is an approved prescription medicine supported by phase 3 trials, not a general weight-loss drug. Single-arm phase 3 trials in POMC/PCSK1 and LEPR deficiency (Clément et al., Lancet Diabetes Endocrinol 2020) showed clinically meaningful weight loss and reduced hunger in most participants. A randomised, placebo-controlled phase 3 trial in Bardet-Biedl and Alström syndromes (Haqq et al., Lancet Diabetes Endocrinol 2022) demonstrated significant weight and hunger reductions in Bardet-Biedl syndrome. These data underpin regulatory approval for defined rare genetic obesity indications.

Educational overview only — no dosing instructions in the public hub.

Commonly reported effects include skin hyperpigmentation and darkening of pre-existing nevi (from melanocortin-1 receptor activity), injection-site reactions, nausea, headache and, in males, spontaneous penile erections. Depression and suicidal ideation have been noted in labeling, warranting monitoring. Because effects and eligibility depend on a specific genetic diagnosis, use requires specialist supervision and genetic confirmation. Grey-market 'research' copies bypass this oversight and carry additional identity, purity and safety risks.

As an approved biologic, only pharmacy-dispensed setmelanotide manufactured under regulatory oversight is legitimate. Non-prescription or 'research use only' versions sold outside this framework lack quality assurance; a third-party certificate of analysis (identity, purity, quantification) is a bare minimum but does not replace the clinical monitoring and genetic confirmation that appropriate use requires.

Approved prescription drug (FDA 2020, EMA 2021) marketed as Imcivree for defined rare genetic obesity indications (POMC, PCSK1 or LEPR deficiency and Bardet-Biedl syndrome), requiring a prescription and specialist supervision. It is not authorised for general or cosmetic weight loss. Non-prescription or 'research use only' setmelanotide sold outside this framework is not approved and carries additional risks.